|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0784 - 0.0784|
|52 Week Range||0.0784 - 0.0950|
|Beta (5Y Monthly)||0.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs. Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company’s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Dr Metters holds a BSc in Biochemistry from the University of Manchester Institute for Science and Technology, and a PhD from Imperial College of Science and Technology in London. Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years. Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, “We are pleased to welcome Dr Metters to ASLAN’s board of directors and look forward to working with her. Kathleen is an accomplished industry leader who brings extensive scientific acumen and global development expertise in immunology. Her insight and experience, combined with that of Dr Neil Graham who recently joined the board, will provide valuable guidance to the management team as ASLAN advances its clinical programs and its pivot to the US. On behalf of the board, I would like to extend our appreciation to Damien Lim for his significant contributions to the growth of the company over the past decade.” Media and IR contacts Emma ThompsonSpurwing CommunicationsTel: +65 6751 2021Email: ASLAN@spurwingcomms.comRobert UhlWestwicke PartnersTel: +1 858 356 5932 Email: firstname.lastname@example.org About ASLAN PharmaceuticalsASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.
Coherent, the provider of lasers and laser-based technologies, deemed the revised buyout offer from II-VI Incorporated as a “Company Superior Proposal.” Per the terms of the revised proposal, the manufacturer of engineered materials and optoelectronic components will pay $170 in cash and 1.0981 shares of II-VI for each share of Coherent (COHR). Coherent intends to terminate the merger agreement with California-based manufacturer and seller of optical and photonic products, Lumentum Holdings (LITE), entered into this January. The company has said the same to Lumentum unless Coherent receives a favorable revised proposal from Lumentum by March 11, 2021. Coherent previously agreed to be acquired for $100 in cash and 1.1851 shares of Lumentum common stock for each share of Coherent. Further, it received two revised proposals from Lumentum. Under the first proposal, each share of Coherent common stock was offered to be exchanged for $175 in cash and 1.0109 shares of Lumentum common stock, while the other proposal offered $170 in cash and 1.0109 shares of Lumentum common stock. Both proposals also included a significantly higher termination fee for accepting competing acquisition proposals. (See Coherent stock analysis on TipRanks) Last month, Coherent also received an unsolicited acquisition proposal from MKS Instruments, in which each share of Coherent common stock was offered to be exchanged for $115 in cash and 0.7473 per share of MKS (MKSI) common stock. Further, MKSI’s revised proposal offered each share of Coherent common stock to be exchanged for $135 in cash and 0.7516 of a share of MKS common stock. Therefore, after a thorough review of all proposals, the company’s board of directors, in consultation with financial and legal advisors, unanimously determined II-VI’s (IIVI) revised acquisition proposal to be the best fit. On Feb. 11, Benchmark Co. analyst Mark Miller downgraded the rating to Hold from Buy on the stock. Meanwhile, the consensus rating on the stock is a Hold. That’s based on unanimous 6 Holds. Looking ahead, the average analyst price target stands at $210.33, putting the downside potential at about 10.6% over the next 12 months. Shares jumped 88.6% over the past year. Related News: Big Lots’ 4Q Profit Beats Analysts’ Estimates As Comparable Sales Rise; Shares Gain 2% Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79% TopBuild Buys Insulation Peer Ozark Foam; Street Sees 16% Upside More recent articles from Smarter Analyst: Paya’s 4Q Revenues Outperform Estimates; Street Is Bullish Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6% Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside
Lumentum Holdings Inc. ("Lumentum") today announced that it has received notice from Coherent, Inc. (NASDAQ: COHR) ("Coherent") of its Board of Directors' determination that an unsolicited acquisition proposal from II–VI Incorporated (NASDAQ: IIVI) ("II-VI") to acquire Coherent in a cash and stock transaction constitutes a "Company Superior Proposal" as defined in the previously announced definitive merger agreement with Lumentum entered into on January 18, 2021 and Coherent's intention to terminate such merger agreement.